DF/HCC Program Affiliation

Prostate Cancer
Cancer Cell Biology

Research Abstract

Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist in the Department of Anesthesiology at Brigham and Women’s Hospital (BWH. Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is faculty member of the Brigham Research Institute Cancer Research Center at BWH. He is additionally a member of the Dana Farber/Harvard Cancer Center Programs in Prostate Cancer and Cancer Cell Biology. He is a Research Affiliate in the Harvard-MIT Division of Health Sciences and Technology (HST). Dr. Farokhzad has extensive experience with the development of therapeutic nanoparticle technologies; most notably he pioneered the high throughput development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored more than 50 papers and is an inventor of more than 40 issued/pending patents. The combinatorial nanoparticle self-assembly technologies that Dr Farokhzad has developed formed the foundation for the launch of two venture-backed biotechnology companies, BIND Biosciences and Selecta Biosciences. These companies are translating the aforementioned academic innovations towards clinical development. He serves as Director on the board of BIND and as Director and Vice Chairman on the board of Selecta. Dr. Farokhzad was named among the Nano50 winners of 2007 by Nanotech Briefs, which awards the most innovative people and design ideas that will revolutionize nanotechnology. In 2009 he was among the 15 recipients across all industries to receive the “All Star Distinguished Achievement Award”, from the Mass High Tech (MHT) Journal for his contributions to Life Sciences industry. Dr. Farokhzad completed his post-doctoral clinical and research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Dr. Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine.

Publications

• Zhang L,Chan JM,Gu FX,Rhee JW,Wang AZ,Radovic-Moreno AF,Alexis F,Langer R,Farokhzad OC.Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform.ACS Nano 2008 Aug;2(8):1696-702.
  19206374
• Farokhzad OC,Langer R.Impact of nanotechnology on drug delivery.ACS Nano 2009 Jan 27;3(1):16-20.
  19206243
• Salvador-Morales C,Zhang L,Langer R,Farokhzad OC.Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups.Biomaterials 2009 Apr;30(12):2231-40.
  19167749
• Alexis F,Basto P,Levy-Nissenbaum E,Radovic-Moreno AF,Zhang L,Pridgen E,Wang AZ,Marein SL,Westerhof K,Molnar LK,Farokhzad OC.HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy.ChemMedChem 2008 Dec;3(12):1839-43.
  19012296
• Dhar S,Gu FX,Langer R,Farokhzad OC,Lippard SJ.Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.Proc Natl Acad Sci U S A 2008 Nov 11;105(45):17356-61.
  18978032
• Farokhzad OC.Nanotechnology for drug delivery: the perfect partnership.Expert Opin Drug Deliv 2008 Sep;5(9):927-9.
  18754745
• Alexis F,Pridgen E,Molnar LK,Farokhzad OC.Factors affecting the clearance and biodistribution of polymeric nanoparticles.Mol Pharm 2008 Jul-Aug;5(4):505-15.
  18672949
• Karnik R,Gu F,Basto P,Cannizzaro C,Dean L,Kyei-Manu W,Langer R,Farokhzad OC.Microfluidic platform for controlled synthesis of polymeric nanoparticles.Nano Lett 2008 Sep;8(9):2906-12.
  18656990
• Peer D,Karp JM,Hong S,Farokhzad OC,Margalit R,Langer R.Nanocarriers as an emerging platform for cancer therapy.Nat Nanotechnol 2007 Dec;2(12):751-60.
  18654426
• Wang AZ,Bagalkot V,Vasilliou CC,Gu F,Alexis F,Zhang L,Shaikh M,Yuet K,Cima MJ,Langer R,Kantoff PW,Bander NH,Jon S,Farokhzad OC.Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.ChemMedChem 200
  18613203
• Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC.Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.Proc Natl Acad Sci U S A 2008 Feb 19;105(7):2586-91.
  18272481
• Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC.Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.Nano Lett 2007 Oct;7(
  17854227
• Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS, Farokhzad OC.Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates.ChemMedChem 2007 Sep;2(9):1268-71.
  17600796
• Bagalkot V, Farokhzad OC, Langer R, Jon S.An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform.Angew Chem Int Ed Engl 2006 Dec 11;45(48):8149-52.
  17099918
• Farokhzad OC, Langer R.Nanomedicine: developing smarter therapeutic and diagnostic modalities.Adv Drug Deliv Rev 2006 Dec 1;58(14):1456-9.
  17070960
• Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC.Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.Biomaterials 2007 Feb;28(5):869-76.
  17055572
• Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R.Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.Proc Natl Acad Sci U S A 2006 Apr 18;103(16):6315-20.
  16606824
• Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C, Kiselyuk A, Teply B, Eng G, Langer R.Microfluidic system for studying the interaction of nanoparticles and microparticles with cells.Anal Chem 2005 Sep 1;77(17):5453-9.
  16131052
• Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R.Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.Cancer Res 2004 Nov 1;64(21):7668-72.
  15520166